A phase I trial of AN 363
Phase of Trial: Phase I
Latest Information Update: 09 May 2016
At a glance
- Drugs AN 363 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; First in man
- Sponsors Saniona
- 09 May 2016 Status changed from planning to suspended, according to a Saniona media release.
- 09 May 2016 According to a Saniona media release, the company announced that the ongoing investigations on the AN363 compound will be put on hold.
- 14 Dec 2015 New trial record